Analysts at Truist Securities admitted that the result for itepekimab, which the companies were hoping to follow their ...

Partners Regeneron and Sanofi say itepekimab only achieved a significantly statistic result in one of two studies.

Bimekizumab demonstrated a favorable safety profile for the long-term treatment of axSpA and PsA, with rates of TEAEs remaining stable over time.

This study presents an important finding on the role of GATA4 in aging and OA-associated cartilage pathology. The evidence supporting the conclusions is compelling, with rigorous in vitro and in vivo ...

Ankyra Therapeutics is a biotech developing anchored immunotherapies aimed at enhancing the therapeutic window of ...

Creative Biolabs recently updated its antibody chip platform, expanding product arrays for phosphorylation signaling and ...

Q: I am severely obese, and my doctor says I have to take immediate actions — medical and personal — or really bad things ...

One-time Amtagvi Treatment Demonstrated Durable Responses and a Five-year Overall Survival Rate of 20% Five-year Follow Up is Unprecedented for Any Therapy in Patients with Advanced Melanoma Previousl ...

One-time Amtagvi Treatment Demonstrated Durable Responses and a Five-year Overall Survival Rate of 20%. Five-year Follow Up is Unprecedented for Any Therapy in Patients with Advan ...

Clearance of ASC50 paves the way for a Phase I trial in patients with mild-to-moderate plaque psoriasis.

Results of the updated systematic review informing the 2024 EULAR recommendations showed that many ARDs are safe to use during pregnancy, lactation, and reproduction.